Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Opioid Efficacy in a C6 Glioma Cell Line Stably Expressing the Human Kappa Opioid Receptor

Ann E. Remmers, Mary J. Clark, Alfred Mansour, Huda Akil, James H. Woods and Fedor Medzihradsky
Journal of Pharmacology and Experimental Therapeutics February 1999, 288 (2) 827-833;
Ann E. Remmers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary J. Clark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfred Mansour
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huda Akil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James H. Woods
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fedor Medzihradsky
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

A C6 glioma cell line stably transfected with the humankappa opioid receptor (κOR) was used to characterize receptor binding and G protein activation via the κOR by a comprehensive series of opioid ligands. The ligand-binding affinity for [3H]5α,7α,8β(-)-N-methyl-N-(7-Cl-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl)benzene acetamide (U69593) was similar to that observed in monkey brain membranes and was 10-fold lower in the presence of sodium and GDP. Both peptide and nonpeptide agonists maximally stimulated [35S]GTPγS binding. The stimulation of [35S]GTPγS binding was blocked by pretreatment of cells with pertussis toxin. Partial stimulation of [35S]GTPγS binding via the κOR was observed for several ligands that are antagonists at the mu opioid receptor, suggesting an additional mechanism of drug action. The ability of isomers of tifluadom and levallorphan to stimulate [35S]GTPγS binding indicates that the chiral carbon of levallorphan, a benzomorphan derivative, imparts a greater degree of stereoselectivity than does the chiral carbon in the benzodiazepine derivative tifluadom. In addition, (−)tifluadom, the less potent isomer of tifluadom, which is also a γ-aminobutyric acidA receptor agonist, stimulated [35S]GTPγS binding. In contrast,d-pentazocine, (+)SKF10047, (+)cyclazocine, andd-ethylketocyclazocine displayed no agonist activity. κOR-selective antagonist norbinaltorphimine competitively inhibited the stimulation of [35S]GTPγS binding by the active isomers of ethylketocyclazocine, cyclazocine, and nalorphine to the same degree, indicating that all three ligands are eliciting an effect via the κOR. The results suggest that these cells express a homogeneous population of κOR, and that their [35S]GTPγS-binding properties make them an excellent means to assess κOR efficacy.

Footnotes

  • Send reprint requests to: Ann E. Remmers. Ph.D., Department of Pharmacology, 1303 MSRB III, 1150 W. Medical Center Drive, University of Michigan, Ann Arbor, Michigan 48109-0632. Email:aremmers{at}umich.edu

  • 1 This work was supported by grants from the U.S. Public Health Service to F.M (DA04087), J.H.W. (DA00254), and H.A. (National Institute on Drug Abuse DA02265 and DA08920).

  • Abbreviations:
    κOR
    kappa opioid receptor
    C6κ
    C6 glioma cells stably expressing the human kappaopioid receptor
    E2078
    [N-methyl-Tyr1,N-α-methyl-Arg7-d-Leu8]dynorphin A-(1–8) ethylamide
    EKC
    ethylketocyclazocine
    U69593
    5α,7α,8β(−)-N-methyl-N-(7-Cl-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl)benzene acetamide
    U50488H
    (trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide
    β-CNA
    β-chlornaltrexamine
    norBNI
    nor-binaltorphimine
    GTPγS
    guanosine-5′-O-(3-thio)triphosphate
    DMEM
    Dulbecco’s modified Eagle’s medium
    CHO
    Chinese hamster ovary
    • Received April 14, 1998.
    • Accepted September 9, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 288 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 288, Issue 2
1 Feb 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Opioid Efficacy in a C6 Glioma Cell Line Stably Expressing the Human Kappa Opioid Receptor
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Opioid Efficacy in a C6 Glioma Cell Line Stably Expressing the Human Kappa Opioid Receptor

Ann E. Remmers, Mary J. Clark, Alfred Mansour, Huda Akil, James H. Woods and Fedor Medzihradsky
Journal of Pharmacology and Experimental Therapeutics February 1, 1999, 288 (2) 827-833;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Opioid Efficacy in a C6 Glioma Cell Line Stably Expressing the Human Kappa Opioid Receptor

Ann E. Remmers, Mary J. Clark, Alfred Mansour, Huda Akil, James H. Woods and Fedor Medzihradsky
Journal of Pharmacology and Experimental Therapeutics February 1, 1999, 288 (2) 827-833;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Interaction of Diclofenac and Quinidine in Monkeys: Stimulation of Diclofenac Metabolism
  • Discriminative Stimulus Effects of Zolpidem in Squirrel Monkeys: Comparison with Conventional Benzodiazepines and Sedative-Hypnotics
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics